StockData

Drugs Made In America Acquisition II Corp. (DMII) stock

DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.23−0.01 (-0.15%)

Close on Nov 18, 2026Market cap $140.15MP/E –Yield –

Drugs Made In America Acquisition II operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Drugs Made In America Acquisition II's operating income for the twelve months ending Sep 30, 2026 was -$556.74K. For fiscal 2025 it was -$488.39K.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$488.39K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$77.01K–
Q2 FY2026Jun 30, 2026-$112.23K–
Q1 FY2026Mar 31, 2026-$132.03K–
Q4 FY2025Dec 31, 2025-$235.47K–
Q3 FY2025Sep 30, 2025-$155.51K–
Q2 FY2025Jun 30, 2025-$38.07K–
Q1 FY2025Mar 31, 2025-$59.33K–

More Drugs Made In America Acquisition II figures

See a number that looks wrong?